TR201922103A2 - The use of specific fractions obtained from the cladotus of Opuntia ficus-indica in cancer treatment. - Google Patents

The use of specific fractions obtained from the cladotus of Opuntia ficus-indica in cancer treatment.

Info

Publication number
TR201922103A2
TR201922103A2 TR2019/22103A TR201922103A TR201922103A2 TR 201922103 A2 TR201922103 A2 TR 201922103A2 TR 2019/22103 A TR2019/22103 A TR 2019/22103A TR 201922103 A TR201922103 A TR 201922103A TR 201922103 A2 TR201922103 A2 TR 201922103A2
Authority
TR
Turkey
Prior art keywords
cladotus
indica
cancer treatment
fractions obtained
opuntia ficus
Prior art date
Application number
TR2019/22103A
Other languages
Turkish (tr)
Inventor
Uludağ Damla
Esra Karadağ Ayşe
Çi̇çek Polat Derya
Evren Okur Mehmet
Karakaş Ni̇hal
Original Assignee
Ankara Ueniversitesi
Istanbul Medipol Ueniversitesi
Saglik Bilimleri Ueniversitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ankara Ueniversitesi, Istanbul Medipol Ueniversitesi, Saglik Bilimleri Ueniversitesi filed Critical Ankara Ueniversitesi
Priority to TR2019/22103A priority Critical patent/TR201922103A2/en
Publication of TR201922103A2 publication Critical patent/TR201922103A2/en
Priority to PCT/TR2020/051407 priority patent/WO2021133362A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Buluş, O. ficus-indica bitkisinin kladotlarından elde edilen ekstrenin, kanser hastalığının önlenmesinde, tedavisinde veya bu hastalıklardan kaynaklanan semptomların giderilmesinde kullanılması ile ilgilidir.The invention relates to the use of the extract obtained from the cladotus of the O. ficus-indica plant in the prevention, treatment or relief of symptoms caused by cancer disease.

TR2019/22103A 2019-12-27 2019-12-27 The use of specific fractions obtained from the cladotus of Opuntia ficus-indica in cancer treatment. TR201922103A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2019/22103A TR201922103A2 (en) 2019-12-27 2019-12-27 The use of specific fractions obtained from the cladotus of Opuntia ficus-indica in cancer treatment.
PCT/TR2020/051407 WO2021133362A1 (en) 2019-12-27 2020-12-27 Use of specific fractions obtained from the cladodes of opuntia ficus-indica plant for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2019/22103A TR201922103A2 (en) 2019-12-27 2019-12-27 The use of specific fractions obtained from the cladotus of Opuntia ficus-indica in cancer treatment.

Publications (1)

Publication Number Publication Date
TR201922103A2 true TR201922103A2 (en) 2020-06-22

Family

ID=76328341

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/22103A TR201922103A2 (en) 2019-12-27 2019-12-27 The use of specific fractions obtained from the cladotus of Opuntia ficus-indica in cancer treatment.

Country Status (2)

Country Link
TR (1) TR201922103A2 (en)
WO (1) WO2021133362A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100523562B1 (en) * 2001-10-29 2005-10-25 한국과학기술연구원 Neuroprotective composition comprising an extract from opuntia ficus-indica and compounds isolated therefrom
KR100963643B1 (en) * 2008-02-11 2010-06-15 한국과학기술연구원 Liver toxicity disorder composition comprising an extract from the seed of opuntia ficus-indica var. saboten and compounds isolated therefrom

Also Published As

Publication number Publication date
WO2021133362A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
BR112022002698A2 (en) IMIDAZOLYL PYRIMIDYNYLAMINE COMPOUNDS AS CDK2 INHIBITORS
CY1125144T1 (en) PHARMACEUTICAL COMPOSITION, METHODS OF THERAPY AND USE THEREOF
BR112022006977A2 (en) BICYCLIC AMINES AS CDK2 INHIBITORS
BR112022002991A2 (en) RIP1 INHIBITORY COMPOUNDS AND METHODS FOR THEIR PREPARATION AND USE
EA202091540A1 (en) ANTIBODIES TO LILRB2
MX2019012233A (en) Anti-sirp alpha antibodies.
BR112022001520A2 (en) Bicyclic peptide complex in heterotandem
EA201891268A1 (en) COMPOUNDS WHICH CAN BE USED AS KINASE INHIBITORS
BR112015029969A2 (en) cancer treatment using pi3 isoform kinase modulators
BR112019021867A2 (en) PHENYL-2-HYDROXY-ACETYLAMINE-2-METHYL-PHENY COMPOUNDS
BR112016013109A2 (en) anti-siglec-8 antibodies and methods of use
EA201892802A1 (en) Derivatives of adenosine for use in the treatment of cancer
CL2022000368A1 (en) Therapeutic uses of anti-tcr delta 1 variable antibodies
MD3728207T2 (en) Quinazolinones as PARP14 inhibitors
BR112017022158A2 (en) compounds, pharmaceutical compositions and use of a compound
BR112019020414A2 (en) compositions and methods to detect and treat prostate cancer using progastrin-binding molecules
BR112018013272A2 (en) compositions and methods for detecting and treating esophageal cancer
WO2016089208A3 (en) Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents
MX2020012800A (en) Cannabinoids and uses thereof.
MX2018014145A (en) Imidazolone compounds as human neutrophil elastase inhibitors.
UY37449A (en) ANTI-CHIKV ANTIBODIES AND USES OF THESE
CY1124457T1 (en) COMPOSITION FOR THE TREATMENT OF COUGH
CL2020003306A1 (en) Bifunctional compositions for the treatment of cancer.
BR112022000120A2 (en) Efficient design and synthesis of lipid-fluorescein conjugates for car-t cell therapy
EA202092824A1 (en) COMBINATION THERAPY